{"id":325422,"date":"2026-10-23T14:42:38","date_gmt":"2026-10-23T09:12:38","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=325422"},"modified":"2026-10-23T14:42:38","modified_gmt":"2026-10-23T09:12:38","slug":"sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/","title":{"rendered":"Sai Life Sciences Share Price Is Up 55% in 2026: Why PL Capital Sees More Returns and What the Valuation Says"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Sai Life Sciences share price traded at Rs 1,389.60 at about 2:30 PM on 23 Oct 2026, down 0.45%, and is up about 55% from the end of 2025. PL Capital (Prabhudas Lilladher) initiated coverage on 21 Oct with a Buy rating and a target of Rs 1,620, which is about 16.6% above today&#8217;s price (my calculation). The stock is still about 18% below its high of Rs 1,697.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">Sai Life Sciences share price is up about 55% in 2026, and PL Capital sees more upside, with a Buy rating and a target of Rs 1,620 issued on 21 Oct. The brokerage expects revenue to grow at a 21% compound rate and net profit at a 26% rate through FY29, helped by growing outsourcing from global pharma firms. The target implies about 55 times forward earnings, so the call depends on growth continuing. This is educational and not a recommendation to buy or sell.<\/p>\n<\/p><\/div>\n<p>Sai Life Sciences share price has nearly doubled from its February low, and a new Buy call from a brokerage after such a run raises a fair question: how much of the growth is already in the price? The company is a contract research, development and manufacturing organisation, known in the market as a CRDMO, which works for global drug makers.<\/p>\n<p>This article on Sai Life Sciences share price covers today&#8217;s move, the PL Capital call, the financials, the valuation, the path of the stock in 2026 and the risks. It is educational and not a recommendation to buy or sell.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\">Click Here &#8211; Get Free Investment Predictions<\/a><\/strong><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Sai_Life_Sciences_Share_Price_Today\" title=\"Sai Life Sciences Share Price Today\">Sai Life Sciences Share Price Today<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#PL_Capitals_Call_on_Sai_Life_Sciences\" title=\"PL Capital&#8217;s Call on Sai Life Sciences\">PL Capital&#8217;s Call on Sai Life Sciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Sai_Life_Sciences_Financials\" title=\"Sai Life Sciences Financials\">Sai Life Sciences Financials<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#The_Latest_Quarter_Behind_the_Sai_Life_Sciences_Share_Price\" title=\"The Latest Quarter Behind the Sai Life Sciences Share Price\">The Latest Quarter Behind the Sai Life Sciences Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Sai_Life_Sciences_Share_Price_The_2026_Journey\" title=\"Sai Life Sciences Share Price: The 2026 Journey\">Sai Life Sciences Share Price: The 2026 Journey<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Sai_Life_Sciences_Share_Price_Valuation\" title=\"Sai Life Sciences Share Price Valuation\">Sai Life Sciences Share Price Valuation<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Risks_Listed_for_the_Sai_Life_Sciences_Share_Price\" title=\"Risks Listed for the Sai Life Sciences Share Price\">Risks Listed for the Sai Life Sciences Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Sai_Life_Sciences_Share_Price_Investor_Views\" title=\"Sai Life Sciences Share Price: Investor Views\">Sai Life Sciences Share Price: Investor Views<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#What_to_Watch_Next_on_the_Sai_Life_Sciences_Share_Price\" title=\"What to Watch Next on the Sai Life Sciences Share Price\">What to Watch Next on the Sai Life Sciences Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#What_is_the_Sai_Life_Sciences_share_price_target\" title=\"What is the Sai Life Sciences share price target?\">What is the Sai Life Sciences share price target?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#How_much_has_the_Sai_Life_Sciences_share_price_gained_in_2026\" title=\"How much has the Sai Life Sciences share price gained in 2026?\">How much has the Sai Life Sciences share price gained in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#What_does_Sai_Life_Sciences_do\" title=\"What does Sai Life Sciences do?\">What does Sai Life Sciences do?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#What_are_the_Sai_Life_Sciences_financials\" title=\"What are the Sai Life Sciences financials?\">What are the Sai Life Sciences financials?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Is_the_Sai_Life_Sciences_share_price_expensive\" title=\"Is the Sai Life Sciences share price expensive?\">Is the Sai Life Sciences share price expensive?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#What_are_the_risks_to_the_Sai_Life_Sciences_share_price\" title=\"What are the risks to the Sai Life Sciences share price?\">What are the risks to the Sai Life Sciences share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#When_are_the_Sai_Life_Sciences_Q2_results\" title=\"When are the Sai Life Sciences Q2 results?\">When are the Sai Life Sciences Q2 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/sai-life-sciences-share-price-up-55-percent-in-2026-pl-capital-buy-target-1620-crdmo-outsourcing-valuation\/#Is_this_article_investment_advice\" title=\"Is this article investment advice?\">Is this article investment advice?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Sai_Life_Sciences_Share_Price_Today\"><\/span><strong>Sai Life Sciences Share Price Today<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Sai Life Sciences share price: point<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Level on 23 Oct 2026 (about 2:30 PM, NSE)<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Previous close<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 1,395.90<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Open<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 1,391.90<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Day high<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 1,429.00<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Day low<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 1,382.90<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Last traded price<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 1,389.60, down 0.45%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Volume so far<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About 5.59 lakh shares<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Market cap<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About Rs 29,650 crore<\/td>\n<\/tr>\n<\/table>\n<p>Sai Life Sciences share price has been quiet on the day, with a range of about 3.3% between the low and the high (my calculation). The new coverage did not trigger a jump, since the weekly close on 19 Oct was Rs 1,389.70, almost the same as today&#8217;s level. That suggests the market is weighing the Buy call against a rich valuation.<\/p>\n<p style=\"margin-top:24px;\"><strong><a href=\"https:\/\/univest.in\/screeners\">Track Sai Life Sciences share price and set alerts on the Univest screeners page<\/a><\/strong><\/p>\n<h2><span class=\"ez-toc-section\" id=\"PL_Capitals_Call_on_Sai_Life_Sciences\"><\/span><strong>PL Capital&#8217;s Call on Sai Life Sciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Sai Life Sciences share price: PL Capital view (21 Oct 2026)<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Detail<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rating<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Buy, initiation of coverage<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Target price<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 1,620 per share<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Upside from Rs 1,389.60 (my calculation)<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About 16.6%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Revenue growth estimate<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">21% compound annual growth through FY29<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Net profit growth estimate<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">26% compound annual growth through FY29<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Capex plan<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 1,100 crore to Rs 1,300 crore by the end of FY27<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Target valuation<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About 55 times forward earnings<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Implied earnings per share at the target (my calculation)<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About Rs 29.5<\/td>\n<\/tr>\n<\/table>\n<p>The brokerage points to the integrated CRDMO model, where one company supports a drug from early research to commercial manufacturing, and to rising outsourcing by global pharmaceutical firms. The capex is meant to expand capacity and deepen long-term client ties. Whether the Sai Life Sciences share price reaches the Rs 1,620 target price depends on whether the earnings growth in the note actually arrives. A target price is an estimate of where a brokerage thinks a stock could trade in about a year, so it can be revised after each quarter.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get stock alerts and track brokerage calls.<\/em><\/p>\n<p><strong>Data note:<\/strong> The PL Capital details are from a report dated 21 Oct 2026. Brokerage targets are opinions, and the note says it is not a buy or sell recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sai_Life_Sciences_Financials\"><\/span><strong>Sai Life Sciences Financials<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Sai Life Sciences share price: yearly metric (Rs crore)<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">FY24<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">FY25<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">FY26<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Revenue<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">1,494.27<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">1,731.35<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">2,241.62<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">EBITDA<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">314.58<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">442.44<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">672.29<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Net profit<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">82.81<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">170.13<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">348.91<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Diluted EPS (Rs)<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">4.53<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">8.61<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">16.43<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Capital expenditure<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">181.69<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">369.28<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">592.96<\/td>\n<\/tr>\n<\/table>\n<p>Revenue rose about 29.5% in FY26 and net profit more than doubled to Rs 348.91 crore, helped by a higher margin and lower interest costs. The EBITDA margin was about 30.0% in FY26 against about 25.6% in FY25 (my calculation). Debt to equity fell to 0.14 as the company raised capital, so the balance sheet is much lighter than it was in FY24.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"The_Latest_Quarter_Behind_the_Sai_Life_Sciences_Share_Price\"><\/span><strong>The Latest Quarter Behind the Sai Life Sciences Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Sai Life Sciences share price: Q1 FY27 (June 2026)<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Figure<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Revenue<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 557.83 crore, up 10.2% YoY and down 9.7% QoQ<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">EBITDA<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 151.55 crore, margin about 27.2% (my calculation)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Net profit<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 73.29 crore, up 21.2% YoY and down 29.7% QoQ<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Net profit margin<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">13.2%, against 17.3% in Q4 FY26<\/td>\n<\/tr>\n<\/table>\n<p>The June quarter was softer than the March quarter, and it explains some of the pause in the Sai Life Sciences share price since September. Growth over the previous year is still healthy, but the margin fell by about 4.6 percentage points from the March quarter at the EBITDA level (my calculation). The Q2 FY27 results are the next test, and I have not verified the date.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sai_Life_Sciences_Share_Price_The_2026_Journey\"><\/span><strong>Sai Life Sciences Share Price: The 2026 Journey<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Sai Life Sciences share price: reference<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Level<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Change to Rs 1,389.60 (my calculation)<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Close in the last week of Dec 2025<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 896.55<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About 55.0% higher<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Low in 2026 (week of 2 Feb)<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 783.85<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About 77.3% higher<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">High in 2026 (week of 7 Sep)<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 1,697.00<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About 18.1% lower<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Weekly close on 14 Sep<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 1,600.50<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About 13.2% lower<\/td>\n<\/tr>\n<\/table>\n<p>The stock rose from the Rs 780 to Rs 800 zone in February to Rs 1,697 in September and has since slipped about 18% from that high. The 55% gain in the headline is therefore measured from a low base and the stock has already given back part of the run. A Buy call at Rs 1,389.60 compares with the Rs 1,600 level at which the stock traded in mid September, so the new target price is close to where the stock stood six weeks ago.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Sai_Life_Sciences_Share_Price_Valuation\"><\/span><strong>Sai Life Sciences Share Price Valuation<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Sai Life Sciences share price: valuation measure<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Figure<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Trailing EPS<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 17.03<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">P\/E at Rs 1,389.60<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About 81.6 times (my calculation)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Industry P\/E<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">35.77 times<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Book value per share<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Rs 116.93<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Price to book at Rs 1,389.60<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">About 11.9 times (my calculation)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Return on equity<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">14.05%<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Debt to equity<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">0.12<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Dividend yield<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">None<\/td>\n<\/tr>\n<\/table>\n<p>At about 81.6 times trailing earnings the Sai Life Sciences share price is more than twice the industry multiple, and the return on equity of 14.05% is modest for that premium. PL Capital&#8217;s target uses about 55 times forward earnings, which is lower than the trailing multiple only because earnings are expected to grow strongly. If growth slows, the premium becomes harder to defend.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_Listed_for_the_Sai_Life_Sciences_Share_Price\"><\/span><strong>Risks Listed for the Sai Life Sciences Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li><strong>Execution risk on capex.<\/strong> Large capital projects can strain financial flexibility if they are delayed or run over budget.<\/li>\n<li><strong>Winning high-value projects.<\/strong> Growth depends on winning big programmes and keeping capacity utilisation high.<\/li>\n<li><strong>Regulatory inspections.<\/strong> Delays in facility inspections by global health authorities can hold up business.<\/li>\n<li><strong>Client demand.<\/strong> Outsourcing demand from global pharma can shift with budgets and drug pipelines.<\/li>\n<li><strong>Competition.<\/strong> Established Indian CRDMO players compete for the same clients.<\/li>\n<li><strong>Valuation.<\/strong> The P\/E of about 81.6 times leaves little room for a miss in growth.<\/li>\n<\/ol>\n<h2><span class=\"ez-toc-section\" id=\"Sai_Life_Sciences_Share_Price_Investor_Views\"><\/span><strong>Sai Life Sciences Share Price: Investor Views<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Sai Life Sciences share price: investor type (my reading)<\/th>\n<th style=\"text-align:left;padding:8px;border:1px solid #DDDDDD;background:#0A0E1A;color:#FFFFFF;\">Points to weigh<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Long-term investor<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">A fast-growing CRDMO with lower debt can suit a multi-year view, but the valuation needs earnings growth to catch up<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Short-term trader<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">The stock needs to hold Rs 1,382.90 and reclaim Rs 1,429 before the pause since September looks over<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Cautious investor<\/td>\n<td style=\"padding:8px;border:1px solid #DDDDDD;\">Waiting for the Q2 FY27 results and margin data gives more evidence than a brokerage target<\/td>\n<\/tr>\n<\/table>\n<p>This is an educational view and not advice. Brokerage targets can be useful, but they carry assumptions that may not hold.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"What_to_Watch_Next_on_the_Sai_Life_Sciences_Share_Price\"><\/span><strong>What to Watch Next on the Sai Life Sciences Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ol>\n<li>The Q2 FY27 results and the EBITDA margin against the 27.2% of the June quarter<\/li>\n<li>The closing price against Rs 1,382.90 and Rs 1,429.00<\/li>\n<li>Further brokerage coverage after the PL Capital initiation<\/li>\n<li>Progress on the capex plan and new client programmes<\/li>\n<li>Any news on regulatory inspections of its facilities<\/li>\n<\/ol>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Sai Life Sciences share price is up about 55% in 2026 at Rs 1,389.60, and PL Capital sees a further 16.6% to its Rs 1,620 target on strong CRDMO growth. The business has improved sharply, but the P\/E near 82 times and a softer June quarter call for care. Read the filings and decide on your own horizon.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/p><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Sai_Life_Sciences_share_price_target\"><\/span><strong>What is the Sai Life Sciences share price target?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> PL Capital (Prabhudas Lilladher) initiated coverage on 21 Oct 2026 with a Buy rating and a target of Rs 1,620. That is about 16.6% above Rs 1,389.60 by my calculation, and it implies about 55 times forward earnings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_has_the_Sai_Life_Sciences_share_price_gained_in_2026\"><\/span><strong>How much has the Sai Life Sciences share price gained in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> It is up about 55% from the close of Rs 896.55 in the last week of Dec 2025 to Rs 1,389.60. It is about 18% below the 2026 high of Rs 1,697 reached in the week of 7 Sep.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_Sai_Life_Sciences_do\"><\/span><strong>What does Sai Life Sciences do?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> It is a contract research, development and manufacturing organisation, or CRDMO, that supports global pharmaceutical companies from early research to commercial manufacturing. Its revenue depends on client programmes and capacity.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_Sai_Life_Sciences_financials\"><\/span><strong>What are the Sai Life Sciences financials?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> FY26 revenue was Rs 2,241.62 crore, up about 29.5%, and net profit was Rs 348.91 crore, up about 105%. In the June 2026 quarter, revenue was Rs 557.83 crore and net profit was Rs 73.29 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_the_Sai_Life_Sciences_share_price_expensive\"><\/span><strong>Is the Sai Life Sciences share price expensive?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The P\/E is about 81.6 times at Rs 1,389.60 against an industry P\/E of 35.77, and the price to book is about 11.9 times. The return on equity is 14.05%, so the valuation relies on strong future growth.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_risks_to_the_Sai_Life_Sciences_share_price\"><\/span><strong>What are the risks to the Sai Life Sciences share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Risks include capex execution, winning high-value projects, regulatory inspection delays, shifts in client demand, competition from Indian CRDMO players and a high valuation. Check each against company filings.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"When_are_the_Sai_Life_Sciences_Q2_results\"><\/span><strong>When are the Sai Life Sciences Q2 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> I have not verified the Q2 FY27 results date, so please check the exchange announcements. The June 2026 quarter showed revenue up 10.2% and net profit up 21.2% from a year earlier.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_this_article_investment_advice\"><\/span><strong>Is this article investment advice?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. It is educational and not a recommendation to buy or sell. Please check the figures against company filings and your own risk profile before you act on anything you read here.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Sai Life Sciences share price target?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"PL Capital (Prabhudas Lilladher) initiated coverage on 21 Oct 2026 with a Buy rating and a target of Rs 1,620. That is about 16.6% above Rs 1,389.60 by my calculation, and it implies about 55 times forward earnings.\"}},{\"@type\":\"Question\",\"name\":\"How much has the Sai Life Sciences share price gained in 2026?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It is up about 55% from the close of Rs 896.55 in the last week of Dec 2025 to Rs 1,389.60. It is about 18% below the 2026 high of Rs 1,697 reached in the week of 7 Sep.\"}},{\"@type\":\"Question\",\"name\":\"What does Sai Life Sciences do?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It is a contract research, development and manufacturing organisation, or CRDMO, that supports global pharmaceutical companies from early research to commercial manufacturing. Its revenue depends on client programmes and capacity.\"}},{\"@type\":\"Question\",\"name\":\"What are the Sai Life Sciences financials?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"FY26 revenue was Rs 2,241.62 crore, up about 29.5%, and net profit was Rs 348.91 crore, up about 105%. In the June 2026 quarter, revenue was Rs 557.83 crore and net profit was Rs 73.29 crore.\"}},{\"@type\":\"Question\",\"name\":\"Is the Sai Life Sciences share price expensive?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The P\/E is about 81.6 times at Rs 1,389.60 against an industry P\/E of 35.77, and the price to book is about 11.9 times. The return on equity is 14.05%, so the valuation relies on strong future growth.\"}},{\"@type\":\"Question\",\"name\":\"What are the risks to the Sai Life Sciences share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Risks include capex execution, winning high-value projects, regulatory inspection delays, shifts in client demand, competition from Indian CRDMO players and a high valuation. Check each against company filings.\"}},{\"@type\":\"Question\",\"name\":\"When are the Sai Life Sciences Q2 results?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"I have not verified the Q2 FY27 results date, so please check the exchange announcements. The June 2026 quarter showed revenue up 10.2% and net profit up 21.2% from a year earlier.\"}},{\"@type\":\"Question\",\"name\":\"Is this article investment advice?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. It is educational and not a recommendation to buy or sell. Please check the figures against company filings and your own risk profile before you act on anything you read here.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sai Life Sciences share price is up about 55% in 2026. PL Capital&#8217;s Buy call and Rs 1,620 target, CRDMO growth, financials, P\/E near 82 times, risks and levels to watch.<\/p>\n","protected":false},"author":36,"featured_media":325421,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[6760,15468,15464,15465,15466,15463,9418,15469,15470,15467],"class_list":["post-325422","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-crdmo-stocks","tag-pharma-outsourcing-stocks","tag-pl-capital-sai-life","tag-sai-life-sciences-buy","tag-sai-life-sciences-results","tag-sai-life-sciences-share-price","tag-sai-life-sciences-target-price","tag-sai-life-sciences-valuation","tag-sai-life-share-news","tag-sailife-share-price"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["325421"],"rank_math_title":["Sai Life Sciences Share Price Up 55% in 2026: PL Capital Target"],"rank_math_description":["Sai Life Sciences share price is up about 55% in 2026. See PL Capital's Buy call and Rs 1,620 target, CRDMO growth, financials, valuation, risks and levels to watch."],"rank_math_focus_keyword":["Sai Life Sciences share price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/sai-life-sciences-share-price-is-up-55-in-2026-why-pl-capital-sees-more-returns.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/325422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/36"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=325422"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/325422\/revisions"}],"predecessor-version":[{"id":325423,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/325422\/revisions\/325423"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/325421"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=325422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=325422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=325422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}